Line 108: | Line 108: | ||
<td colspan = 6 align="left"> | <td colspan = 6 align="left"> | ||
<p class="introduction"> | <p class="introduction"> | ||
− | <h3>Modular | + | <h3>Modular Design for crRNA</h3> |
<p>Our strategy to create crRNAs, which bind both the Cas13a protein with organism specificity (crRNA Lbu does not bind Cas13a Lsh) and the target sequence with point-mutation sensitivity, is designed to allow easy prototyping of target binding sequences. Our crRNA template for transcription consists of two DNA strands sharing complementary regions that can therefore be amplified using PCR into a full double-stranded template. The non-template (NT) strand contains the T7 promoter site and the scaffold region of the transcript that will specifically bind the Cas13a. The template strand (T) contains part of the scaffold region, so that it is complementary to the NT strand, and the target binding region. In a one-batch reaction using the Klenow DNA polymerase and the T7 RNA polymerase, the two strands bind in the scaffold region, which serves as a primer for Klenow, they get amplified into a complete double stranded DNA template, and finally transcribed into our crRNA <b>(Figure 1)</b>. This modular design allows a fast and cost-effective creation of crRNAs since only the pathogen specific T strand has to be newly designed and synthesized as a oligo to accommodate for new targets. This prototyping gives the opportunity to screen all kind of pathogens with our system easily. This can be combined with our <a class="myLink" href="/Team:Munich/Software">software</a> for target screening, which can be used to verify that the target strand design does not lead to off target binding in human transcriptome and microbiome. | <p>Our strategy to create crRNAs, which bind both the Cas13a protein with organism specificity (crRNA Lbu does not bind Cas13a Lsh) and the target sequence with point-mutation sensitivity, is designed to allow easy prototyping of target binding sequences. Our crRNA template for transcription consists of two DNA strands sharing complementary regions that can therefore be amplified using PCR into a full double-stranded template. The non-template (NT) strand contains the T7 promoter site and the scaffold region of the transcript that will specifically bind the Cas13a. The template strand (T) contains part of the scaffold region, so that it is complementary to the NT strand, and the target binding region. In a one-batch reaction using the Klenow DNA polymerase and the T7 RNA polymerase, the two strands bind in the scaffold region, which serves as a primer for Klenow, they get amplified into a complete double stranded DNA template, and finally transcribed into our crRNA <b>(Figure 1)</b>. This modular design allows a fast and cost-effective creation of crRNAs since only the pathogen specific T strand has to be newly designed and synthesized as a oligo to accommodate for new targets. This prototyping gives the opportunity to screen all kind of pathogens with our system easily. This can be combined with our <a class="myLink" href="/Team:Munich/Software">software</a> for target screening, which can be used to verify that the target strand design does not lead to off target binding in human transcriptome and microbiome. | ||
</p> | </p> | ||
Line 119: | Line 119: | ||
<tr><td colspan=6 align=center valign=center> | <tr><td colspan=6 align=center valign=center> | ||
− | <h3>Variety of | + | <h3>Variety of Detectable Targets</h3> |
<p>Before demonstrating if we could discriminate bacterial and viral sequences, we needed to determine if our detection circuit worked across pathogens. <i>Escherichia coli</i> 16S rRNA had been our first target, as Dr. Pardee had advised us to use the most simple and accessible RNA sequence. For other targets, we were advised different pathogens through our series of <a class="myLink" href="/Team:Munich/HP/Gold_Integrated">interviews with experts</a>, but we could not easily access most of the pathogens due to safety restrictions in our lab. We therefore looked at <i>B. subtilis</i> as a second bacterial target that shares sequence homology with <i>E. coli</i>, and we used <i>in vitro</i> transcribed RNA for viruses (Norovirus, Hepatitis C, and Q5 beta). We describe quickly the sequences chosen and then present our detection results.</p> | <p>Before demonstrating if we could discriminate bacterial and viral sequences, we needed to determine if our detection circuit worked across pathogens. <i>Escherichia coli</i> 16S rRNA had been our first target, as Dr. Pardee had advised us to use the most simple and accessible RNA sequence. For other targets, we were advised different pathogens through our series of <a class="myLink" href="/Team:Munich/HP/Gold_Integrated">interviews with experts</a>, but we could not easily access most of the pathogens due to safety restrictions in our lab. We therefore looked at <i>B. subtilis</i> as a second bacterial target that shares sequence homology with <i>E. coli</i>, and we used <i>in vitro</i> transcribed RNA for viruses (Norovirus, Hepatitis C, and Q5 beta). We describe quickly the sequences chosen and then present our detection results.</p> | ||
<h4>Noro virus</h4> | <h4>Noro virus</h4> | ||
Line 162: | Line 162: | ||
</td> | </td> | ||
<td class="verticalColumn" colspan=3 align=center valign=center> | <td class="verticalColumn" colspan=3 align=center valign=center> | ||
− | <h3>Orthogonality of | + | <h3>Orthogonality of Detection</h3> |
<p> | <p> | ||
We then set out to differentiate viral sequences from bacterial sequences. Assuming the risk of sample contamination from the patient’s own bacteria is high, we decided to first use the crRNA from a virus to screen against different targets. We chose the Norovirus crRNA and looked at the activation of Cas13a under the presence of 30 nM of Norovirus, <i>E. coli</i> or HCV as targets <b>(Figure 4)</b>. We found that only the Norovirus target lead to a great increase in RNase Alert cleavage, and that our detection mechanism is therefore highly orthogonal and specific. | We then set out to differentiate viral sequences from bacterial sequences. Assuming the risk of sample contamination from the patient’s own bacteria is high, we decided to first use the crRNA from a virus to screen against different targets. We chose the Norovirus crRNA and looked at the activation of Cas13a under the presence of 30 nM of Norovirus, <i>E. coli</i> or HCV as targets <b>(Figure 4)</b>. We found that only the Norovirus target lead to a great increase in RNase Alert cleavage, and that our detection mechanism is therefore highly orthogonal and specific. | ||
Line 182: | Line 182: | ||
<tr><td colspan=6 align=center valign=center> | <tr><td colspan=6 align=center valign=center> | ||
− | <h3>Discussion and | + | <h3>Discussion and Conclusion</h3> |
<p> | <p> | ||
We found that it was quite simple to prototype a variety of targets with our crRNA template system, where the target binding region could be easily exchanged with a new primer. We found that in most cases, the Cas13a detection circuit worked reliably. However, it should be noted that we were unsuccessful at detecting the virus Q5 beta (data not shown), and that <i>in vivo</i>-extracted targets still bear <a class="myLink" href="/Team:Munich/Cas13a">the risk of contamination</a>. We did not experimentally test the point-mutation sensitivity of Cas13a (as this was characterized elsewhere<sup><a class="myLink" href="#ref_2">2</a></sup>), nor did we optimise the target sequence within one organism. However, we developed a <a href="/Team:Munich/Software" class="myLink">software</a> that can verify the secondary structure of the crRNA and screen cross-talk between targets and crRNA, so that sequence optimisation can be done more systematically. What we achieved here is a proof-of-principle that our discrimination between viral and bacterial sequences is efficient and simple to implement. We are confident that with the right tools for sequence-optimisation, a general scheme for discriminating between the most common bacterial and viral infections can be built. We have already shown that our readout circuit can be used to detect Norovirus without false positives from other common pathogens.</p> | We found that it was quite simple to prototype a variety of targets with our crRNA template system, where the target binding region could be easily exchanged with a new primer. We found that in most cases, the Cas13a detection circuit worked reliably. However, it should be noted that we were unsuccessful at detecting the virus Q5 beta (data not shown), and that <i>in vivo</i>-extracted targets still bear <a class="myLink" href="/Team:Munich/Cas13a">the risk of contamination</a>. We did not experimentally test the point-mutation sensitivity of Cas13a (as this was characterized elsewhere<sup><a class="myLink" href="#ref_2">2</a></sup>), nor did we optimise the target sequence within one organism. However, we developed a <a href="/Team:Munich/Software" class="myLink">software</a> that can verify the secondary structure of the crRNA and screen cross-talk between targets and crRNA, so that sequence optimisation can be done more systematically. What we achieved here is a proof-of-principle that our discrimination between viral and bacterial sequences is efficient and simple to implement. We are confident that with the right tools for sequence-optimisation, a general scheme for discriminating between the most common bacterial and viral infections can be built. We have already shown that our readout circuit can be used to detect Norovirus without false positives from other common pathogens.</p> |
Revision as of 15:52, 1 November 2017
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|